Induction to erythroid differentiation of K562 cells by 1-beta-D-arabinofuranosylcytosine is inhibited by iron chelators: reversion by treatment with hemin.
Erythroid differentiation of human leukemic K 562 cells is inhibited by the iron chelator desferrioxamine (DF). In addition, desferrioxamine induces an increase of uptake of hemin. When hemin is added to the culture medium, the DF-mediated inhibitory effects on erythroid induction are reversed. Briefly, hemin allows hemoglobin synthesis by K 562 cells induced to erythroid differentiation by 1-beta-D-arabinofuranosylcytosine (ara-C) and treated with 12.5 micrograms/ml DF. In addition, it was found that hemin treatment leads to a reversion of inhibition of K 562 cell proliferation mediated by 50-75 micrograms/ml DF. This effect of hemin was also detected in other cultured human tumor cell lines (B-lymphoid, erythroleukemic and from breast carcinomas, melanomas and kidney carcinomas).
Feriotto
G
G
Istituto di Chimica Biologica, Università di Ferrara, Italy.
Nastruzzi
C
C
Barbieri
R
R
Gambari
R
R
D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D003561:Cytarabine / Q000494:pharmacology*; D003676:Deferoxamine / Q000494:pharmacology*; D004920:Erythropoiesis / Q000187:drug effects*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006418:Heme / Q000031:analogs & derivatives*; D006427:Hemin / Q000494:pharmacology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D004915:Leukemia, Erythroblastic, Acute / Q000378:metabolism / Q000473:pathology*
D006131:Growth Inhibitors; D006454:Hemoglobins; D003561:Cytarabine; D006418:Heme; D006427:Hemin; D003676:Deferoxamine